This article is about my experience with cancer research. April is cancer awareness and fundraising month. I thought it would be interesting to analyze what’s going on behind the scenes of cancer research. I was a cancer researcher for over 3 years at the Ontario Cancer Institute (OCI) from 1972 to 1975 and I will share some insider experiences here.
1. Publish or perish
Our supervisors said: “publish or perish”. In other words all the experiments we did needed to fit into the larger picture the group was working on. And the results should be different, interesting and most of all publishable. There had to be significant differences between experimental groups and controls. This was a requirement by publishers of medical journals would accept them for publication. There were often two or three manuscript revisions where the content was “massaged”. I had to pay attention to proper wording and comparing or opposing the results with other publications. This way the publisher deemed the manuscript “publishable”.
2. Fund raising awareness
One of the major fund sources for cancer research in Canada was the MRC (Medical Research Council of Canada), which has been replaced by the Canadian Institutes of Health Research (CIHR) in 2000. Without money there is no cancer research, so everybody was aware of the policies and expectations of the fund source.
3. Mouse model versus human tissue based research
My work was in the immunology section of the biophysics department, where researchers perform basic medical research at the OCI. In this department much research had already been performed separating cell populations in a mouse model to determine what cell types were needed to initiate an immune response. The B cells in mammals are antibody-producing cells of the immune system that protect from viruses. T cells are lymphocytes, which the body processed in the thymus. They turn into killer cells, which can attack parasites and also cancer cells. I was working in this area.
Cell separation experiments and doubts about mouse research
We did cell separation experiments. With this method I was able to separate cells according to cell size and collect them in vials. Subsequently I did remix experiments. The purpose was to find out which cell types were able to mount an immune response. My supervisor suggested the use of a mouse tumor cell line as targets. I started questioning whether a mouse model would be the appropriate model to study human cancer biology. But my superiors were not in agreement. The “holy grail” was that to work in a mouse model (mouse mammalian cells). The assumption that this should also work in the human situation (human mammalian cells).
My Experience With Cancer Research
4. Non-medical researchers in cancer research
This is a thorny issue, but a reality. My immediate supervisor in cancer research had a PHD in physics. His physics degree was perfect for sorting out density issues for cell separation experiments. The co-chair of the immunology department had a PHD in biology. His qualification was good for conducting mouse experiments. Both of them felt somewhat insecure when I asked questions. I wanted to know how relevant mouse experiments were for the examination of human cancer conditions. As I needed to publish my experiments, I had to quiet down and concentrate on the mouse model the team was working on. For a while this could even be exciting as we were studying the cell interaction between macrophages and T cells to mount a cell-mediated immune response.
5. Regulation of the cancer research industry
After playing with cell cultures for 2 ½ years it was time for me to reach out to get a job in the cancer research field or else go back to medicine. In1975 there was no equal opportunity legislation in place that would have protected me as a landed immigrant from discrimination. The reality in 1975 was that only Canadian born physicians who attended a Medical School in Canada could become a director of a cancer research facility in Canada. The rules for me (I had left Germany right after my rotating internship) were that I had to go through further medical training and pass the Canadian licensing exam (LMCC), which I did eventually at McMaster University in Hamilton, Ontario.
Interview with Dr. McCulloch
One final attempt to shed light on my options was an interview with the “big boss” at the Ontario Cancer Institute at the time, a physician cancer researcher, Dr. Ernest A. McCulloch, for whom I had great respect. He was a sharp thinker and had vision, and he was a fellow physician. I asked him what he would do on the long-term, if he was in my place. He said that in the long-term with my medical background it would be a lot more satisfying for me to get back into medicine and practice medicine. However, he wanted me to go on for another 1 or 2 years and publish more papers together with my supervisors.
My decision to leave cancer research
I decided for myself right there that I would leave cancer research and I prepared quietly for my exit. Within a short time I got a position to work as an intern at a hospital at McMaster University and in the spring of 1978 I passed the LMCC (licensing) exam. As a fully licensed physician in Canada, I was no longer interested in “slave work” in cancer research. I also left the cold winters of Ontario behind and went to the west, to British Columbia.
6. Future vision of medical cancer research
Research has come a long way. Recently I came across a new breast cancer protocol, which is non-toxic, without chemotherapy and without radiation. It is so unconventional that the US research team, aware of the politics in the US, decided to do the initial trials in the Caribbean. I wrote a blog about this new breast cancer treatment protocol, which I believe will become the future standard for breast cancer therapy and perhaps even for other cancers.
Alternative breast cancer treatment
In Germany and Switzerland an alternative breast cancer treatment consists of with mistletoe extracts. This is a non-toxic plant chemotherapy, which slows down tumor growth. It has a dual action, namely a chemotherapeutic effect, but at the same time an immune system stimulating effect. Here is a study going back to 2001, which is still relevant. There was a 40% long-term survival benefit in the Iscador group when compared to a control group without treatment. Normally, oncologists jump at such an excellent chemotherapeutic agent as they even consider chemotherapeutic agents that with a 25% beneficial survival effect a good treatment option. However, as the medication is a simple mistletoe extract and cannot be patented, Big Pharma is not interested in marketing this. As a result cancer treatment protocols in Europe are significantly different from those in North America.
The future of cancer treatments
In the future I would expect that non-toxic treatment methods for any type of cancer will be more successful than any chemotherapeutic or radiation treatment approaches as both interfere with the immune function, which is what will kill the patient at the end. Cancer is a disease where the immune system fails. So, cancer patients need teaching how to stimulate their immune system. This is the only thing that controls cancer on the long-term.
You will hear more about epigenetic switches as often a cancer producing substance will turn off a gene (epigenetic switch) and this causes cancer. Remove what throws that switch into the off position or introduce a healing agent that resets the switch and the cancer will get eliminated.
7. Prevention of cancer
Researchers noticed that herbs, spices, vitamins and minerals contain the most powerful cancer preventatives. Did you know that curcumin, derived from the Indian spice turmeric, prevents a number of cancers? Similarly, vitamin D3 at high enough doses (4000 to 5000 IU per day) has been shown to prevent cancers. Linus Pauling showed long time ago that vitamin C at high enough dose would be an antioxidant and would stimulate the immune system and thereby be a cancer preventative. It works together with a detoxifying antioxidant, glutathione in the liver to neutralize any free radicals, which are aggressive chemicals that cause cancer.
Learning from risk factors for cancer
There are many other vitamins and minerals that I have explained elsewhere, which are needed together with organic food to give you the building blocks for a stable cell metabolism. This in turn will strengthen the immune system to defend you from toxins of the environment. A simple step like a daily exercise routine can cut your cancer risk down to 50% compared to those who elect to not exercise. Did I mention the importance of quitting smoking and cutting out alcohol? The “quit smoking” part has been known for some time.
Alcohol is a cell poison and can cause cancer
At the Anti-Aging conference in Las Vegas in December 2011 I learnt about the importance of alcohol exposure that causes cancer. Even smaller doses of alcoholic beverages over a long period of time can cause cancer. First I thought it would be a big deal to quit alcohol entirely. But since I have quit the modest few drinks per month, I actually have not missed them at all! I strongly believe in cancer prevention, so quitting alcohol completely was only one small step in this overall objective. In view of the recent statement by the WHO that 70% of all deaths are caused by smoking and drinking of alcoholic beverages, it behooves us to change our lifestyles, if we are at all interested in a healthy long life.
Conclusion
Nothing has changed in cancer research circles since the time when I was part of it. Basic cancer research involving animal experiments is necessary. But in my opinion cancer research should be more human-centered using human cell lines in culture and using clinical trials. Ultimately cancer research needs to invent and develop new non-toxic cancer therapies to cure cancer patients.
More on cancer in general and on specific cancers: http://nethealthbook.com/cancer-overview/
Last edited Nov. 6, 2014
About Ray Schilling
